Bli medlem
Bli medlem

Du är här

2017-01-31

Nexstim Oyj: Neurosurgeons from Germany and U.S.A. report on their clinical experience of using Nexstim NBS system

Press release, Helsinki, 31 January 2017, at 3pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim
" or "Company
"), a medical technology company with a pioneering navigated non-invasive
brain stimulation system, announces that, in a recently published clinical
article, neurosurgeons report clinical benefits of using Nexstim NBS Brain
Mapping technology, for pre-surgical localization of the motor cortex .

In a recent multi-center study at Departments of Neurosurgery at Charite
Univärsitetsmedizin, Berlin, Teknische Universität Munchen and University of
California San Francisco(1)outcomes of brain surgery performed because of
tumor metastases in the central brain areas were compared between two
observational patient cohorts. Cohort 1 included 120 consecutive patients in
whom preoperative localization of the motor cortex in relation to the
metastasis was performed with Nexstim NBS system. Cohort 2 included 130
consecutive patients in whom NBS motor mapping was not performed because of
organizational issues.

Results in Cohort 1 were significantly better than those in Cohort 2 both in
regard to complete tumor removal and likelihood of poor post-operative motor
function. Specifically, the NBS mapped patients had a lower rate of residual
tumor on postoperative magnetic resonance imaging (odds ratio 0.3025; 95%
confidence interval 0.1356-0.6749). Further, surgery-related paresis was less
likely in the NBS group (Cohort 1 vs. Cohort 2; patients improved in
long-term follow-up: 30.8 vs. 13.1%, unchanged: 65.8 vs. 73.8%, worse: 3.4
vs. 13.1%; p = 0.0002).

In the operating room, the duration of surgery was approximately 30 minutes
shorter (Cohort 1: 128.8 ± 49.4 min vs. Cohort 2: 158.0 ± 65.8 min; p =
0.0002) and the surgical skull opening (craniotomy size) 33% smaller (Cohort
1: 16.7 ± 8.6 cm2 vs. Cohort 2: 25.0 ± 17.1 cm2; p<0.0001) in the NBS mapped
patients.

1 Krieg SM, Picht T, Sollmann N, Bährend I, Ringel F, Nagarajan SS, Meyer B,
Tarapore PE. Resection of Motor Eloquent Metastases Aided by Preoperative
nTMS-Based Motor Maps-Comparison of Two Observational Cohorts. Front Oncol.
2016 Dec 21;6:261. doi: 10.3389/fonc.2016.00261. PubMed PMID: 28066717.

Commenting on this positive clinical data, Jarmo Laine, Vice President Medical
Affairs stated:
"We at Nexstim are excited about the clinical experience of using our
technology as part of the care path in these severely afflicted patients. The
results reported by the teams at these leading University hospitals are very
encouraging"

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website
www.nexstim.comor by telephone:

Nexstim
+447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in
brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is
the first and only FDA cleared and CE marked system based on navigated
Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the
speech and motor cortices of the brain. Based on the same technology
platform, the Company has developed a system called Navigated Brain Therapy
(NBT®) which is CE marked for the treatment of chronic neuropathic pain,
major depression and stroke. Nexstim shares are listed on the Nasdaq First
North Finland and Nasdaq First North Sweden. For more information please
visitwww.nexstim.com

Neurosurgeons from Germany and USA report on their clinical experiene
http://hugin.info/138152/R/2074746/780027.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.